The Arizona Center for Innovation (AzCI) is pleased to announce that the Flinn Foundation has selected MSDx, Inc. to receive grant funding and program services through the Foundation’s 2013 Bioscience Entrepreneurship Program. MSDx is a personalized medicine diagnostics company developing blood test products for monitoring disease activity in neurological disorders such as Multiple Sclerosis (MS). The Foundation funding will be used to support further development of the MSDx blood testing technology.
Author Archive: AZBio
November and December Deadlines for Small Business Cancer Technology Grant Funding Opportunities
The Small Business Innovation Research & Small Business Technology Transfer (SBIR & STTR) Programs are government set-aside programs that represent one of the largest sources of early-stage technology financing in the United States. The National Cancer Institute (NCI) SBIR/STTR Programs are designed to catalyze the development of innovative technologies and therapeutics to advance cancer research, prevention, detection, and treatment.
In FY2014, the set-asides reserved for small businesses have increased from 2.5% to 2.7% for SBIR and 0.35% to 0.40% for STTR. Please note the budget caps for the specific funding opportunity you are applying for, as they cannot be exceeded. We encourage you to review the opportunities below and consider applying for funding to the NCI SBIR & STTR Programs. NCI SBIR Development Center Program Directors are available to discuss ideas and opportunities with you. |
||||||
|
||||||
|
||||||
|
||||||
|
||||||
|
||||||
How to Apply For resources and tips for applying, please click here. Please visit http://sbir.cancer.gov/ to learn more about the NCI SBIR & STTR Programs. |
TGen-Scottsdale Healthcare research shows ability to do whole genome and whole transcriptome sequencing for patients with advanced cancers
Faster analysis of genetic variations should uncover new drug targets and pathways even as cancers mutate beyond initial therapiesContinue reading
Absence of the SMG1 protein could contribute to Parkinson’s and other neurological disorders
TGen-led study links lack of SMG1 to protein aggregates associated with Parkinson’s disease, forms of dementia and multiple systems atrophy (MSA)Continue reading
UA College of Medicine – Phoenix, SynDaver Strike Formal Collaboration
Simulation Technology Improves Medical Education, Creates JobsContinue reading
VisionGate Presents Clinical Data At IASLC Meeting Showing Its Cell-CT™ 3D Imaging Platform Detects Lung Cancer With High Sensitivity And Specificity
SYDNEY and PHOENIX, Oct. 28, 2013 — VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today reported clinical data showing that its automated 3D cell imaging platform, the Cell-CT™, can detect lung cancer in sputum samples with high sensitivity and specificity. The data was presented at the International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer.Continue reading
SEC Releases Crowd Funding Rules for Non-Accredited Investors Under the JOBS Act.
On October 25, 2013, The Securities and Exchange Commission (SEC) released the Proposed Rules to govern the implementation of crowd funding by non-accredited investors under the JOBS Act. Comments will be open for a 90 day public comment period from the date that the proposed regs appear on the Federal Register. (As of this writing, the proposed regs have not yet been posted.) Continue reading
UA President Outlines The Basics Of The GME Crisis and Offers A Solution
Ann Weaver Hart, President of the University of Arizona outlines the basics of the GME Crisis and offers a solution
Scottsdale diagnostics company licenses biomarker technologies developed at ASU Biodesign with support from AzTE
SCOTTSDALE, Arizona, October 25, 2013 – Provista Diagnostics, Inc., a leading molecular diagnostics company focused on developing and commercializing proprietary diagnostic, prognostic and predictive tests for cancers affecting women, has licensed a series of biomarker technologies developed by researchers at the Biodesign Institute of Arizona State University. Provista will evaluate the technologies for use in the early detection of breast cancer, ovarian cancer and HPV.